| abstract |
PROBLEM TO BE SOLVED: To provide a kappa myeloma antigen chimeric antigen receptor and its use. The present invention provides compositions and methods for treating KMA-expressing malignancies, including chimeric antigen receptors (CARs) and CAR-containing T cells (CAR T cells). The present invention also provides methods and compositions comprising CAR T cells that co-express other antitumor agents, including cytokines and antibodies. The present invention is a chimeric antibody receptor (CAR), such as CAR, that contains an intracellular signaling domain that is specific for Kappa myeloma antigen (KMA) but is capable of inducing an anti-KMAT cell response. The subjects are methods of treating multiple myeloma and related disorders by administering T cells containing, and KMA-specific CAR. [Selection diagram] None |